source
- Early Inclusion of China Boosts Global Biotech Clinical Development EfficiencyMany global biotech firms still treat China as a later-stage commercial market, adding it only after key development decisions. This practice often forces costly bridging studies, extends timelines…
- BMS terminates Cellares partnership after cell therapy platform fails to meet Breyanzi production needs, prompting layoffsBristol Myers Squibb has ended its collaboration with manufacturing specialist Cellares after the Cell Shuttle system could not satisfy the requirements for producing the approved CAR‑T therapy Bre…